Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Induction Chemotherapy

NCT05503355 is registered in ClinicalTrials.gov with BioSight Ltd. as lead sponsor.

NCT NCT05503355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05503355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Induction Chemotherapy
Lead sponsor
BioSight Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 17, 2022
Completion date
December 1, 2025
Enrollment
80 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

aml, adult